What is the best treatment for pertussis? by Tubbs, Charles G. et al.
1096 VOL 54, NO 12 / DECEMBER 2005  THE JOURNAL OF FAMILY PRACTICE
From the Family Practice Inquiries Network
CLINICAL INQUIRIES
What is the best treatment 
for pertussis?
■ Evidence summary
A 2005 Cochrane review of 11 RCTs and
1 quasi-randomized trial, with a total of
1720 adults and children, investigated sev-
eral antibiotics for treatment and prophy-
laxis of pertussis. The outcome measures
used to assess the efficacy of antibiotic
treatment or prophylaxis vary between the
trials and most of them did not report 
the immunization status of the partici-
pants. The Cochrane review included 1
meta-analysis of 3 studies with 252 partic-
ipants, comparing azithromycin for 3 days, 
erythromycin estolate for 7 days, and 
A short-term course of erythromycin, azithromycin,
or clarithromycin is as effective as a long-term 
(2-week) erythromycin therapy in eradicating
Bordetella pertussis from the nasopharynx
(strength of recommendation [SOR]: A; based on
one meta-analysis of randomized controlled trials
[RCTs]). Evidence is insufficient to determine the
benefit of antibiotic prophylaxis for pertussis 
contacts. However, due to high mortality and 
morbidity, prophylaxis is recommended for 
families who have an infant less than 6 months 
old (SOR: C; based on expert opinion). 
E V I D E N C E - B A S E D A N S W E R
Fewer doses and lower cost 
make compliance more likely
I found this Clinical Inquiry on the treatment and
prophylaxis of Bordetella pertussis invaluable as
it addresses ease of dosing and cost, 2 things
important in my pediatric community health 
practice with its inherent financial and social 
constraints. The alternatives suggested are easy
to use and are as equally effective as the first-line
therapy of erythromycin estolate, the long-term
treatment recommended by the CDC and the 
AAP. These alternatives, clarithromycin and
azithromycin, require either twice a day or a once 
a day dosing for 7 days or 3 days respectively,
can be accommodated in busy households, thus
promoting better compliance. 
The cost of medication also relates to compli-
ance. The cost difference between the first-line
therapy and the alternative therapy is significant,
and may be as much as $89. In an underinsured
population, this out-of-pocket cost for the 
alternatives would prove prohibitive, resulting 
in decreased compliance. Where cost is not a
great issue and concerns of compliance impor-
tant, choosing the short-term treatment may be a
preferable option. For the financially strapped, 
the 1-week regimen of erythromycin estolate
would be preferable. The importance of counsel-
ing cannot be overstated in all dosing regimens, 
especially in those with a more difficult dosing
schedule and in cases of prophylaxis in a house-
hold with an infant less than 6 months old. 
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Due to high 
mortality, pertussis
prophylaxis 
is recommended
for families with
an infant 
<6 months old
FAST TRACK
clarithromycin for 7 days (short-term
treatment) with erythromycin estolate for
fourteen days (long-term treatment). The
study showed equal efficacy in eradication
of B pertussis from the nasopharynx of
99.2% to 97.7% (absolute risk reduction
[ARR]=1.44%; 95% confidence interval
[CI], –1.58 to 4.46). There were fewer side
effects with the short-term treatment
(32.1% vs 48.9%; ARR=16%; 95% CI,
7.84 to 25.84).1
A large, multicenter RCT of 477 chil-
dren of 6 months to 16 years of age
demonstrated that a 5-day treatment with
azithromycin eradicated B pertussis from
the nasopharynx as effectively as a 10-day
course of erythromycin estolate.2 Similarly,
trimethoprim/sulfamethoxazole proved as
effective as erythromycin in eliminating B
pertussis from the nasopharynx. 
Although tetracycline and chloram-
phenicol are effective treatments for per-
tussis, they are not recommended because
of their side effects.1 Six randomized trials
failed to show any statistically significant
difference between antibiotics and placebo
on frequency and severity of cough or
duration of pertussis disease.1 A random-
ized, placebo-controlled trial studied 300
household contacts of children with 
culture-positive pertussis. There was no
statistically significant difference in either
the frequency of pertussis disease or rate of
positive cultures in household contacts
between the erythromycin group (2.1%)
and the placebo group (5.1%)
(ARR=2.95%; 95% CI, –1.21 to 7.11).1
Another Cochrane review of 8 trials
examined the effectiveness of the sympto-
matic treatment of cough in children and
adults with pertussis. There were many
problems with the methodological quality
of these trials, including small sample sizes
and poor reporting of the methods.
T A B L E
Antibiotics for treatment and prophylaxis 
of pertussis in children and adults
FIRST-LINE THERAPY DOSAGE FOR CHILDREN DOSAGE FOR ADULTS COST*
Erythromycin 40–50 mg/kg orally or 1–2 g orally or 56 tabs (500 mg),
intravenously in 4 divided intravenously in 4 divided $16 (generic) 
doses for 14 days5,7 doses for 14 days5,7
ALTERNATIVE THERAPY IF PATIENT DOESN’T TOLERATE ERYTHROMYCIN
Clarithromycin 15–20 mg/per kg orally 500 mg orally every 12 20 tabs (500 mg), $78 
divided every 12 hours hours for 7 days5 28 tabs (500 mg),
for 10–14 days7 or $109 (generic)
14-15 mg/kg orally 
divided every 12 hours 
for 7 days1,5
Azithromycin 10–12 mg/kg orally as 500 mg orally once, then 5 tabs (500 mg), $75 
single daily dose for 5 to 250 daily on days 2–55,7 7 tabs (500 mg),
7 days5,7 or $105 (no generic)
10 mg/kg orally single 
daily dose for 3 days1
Trimethoprim- 8 mg of TMP, 40 mg/kg 160 mg of TMP, 800 mg 28 tabs $8 (generic) 
sulfamethoxazole SMX per kg orally divided SMX orally (1 tab DS)
every 12 hours for 14 every 12 hours for 14 
days5,7 days5,7
All these therapies have gastrointestinal side effects and risk for hypersensitivity reactions. 
*Approximate retail price for adult dose. Available at: http://www.drugstore.com. Accessed on June 28, 2005. 
JFP_1205_CI.Final  11/16/05  2:39 PM  Page 1097
Good news for 
the underinsured:
relatively 
inexpensive
antibiotics are
among the drugs
effective against
pertussis
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FAST TRACK
Diphenhydramine, pertussis immuno-
globulin, corticosteroids and salbutamol
were compared with placebo. There 
were no statistically significant differences
in coughing paroxysms, mean number 
of whoops per 24 hours or in duration of
hospital stay between these interventions
and placebo.3
Extracorporeal circulatory life support
has been used to maintain perfusion for
patients with severe disease. The mortality
of these patients is very high.4 No RCTs of
the effectiveness of this intervention has
been performed.
Recommendations from others
The Centers for Disease Control and
Prevention recommends erythromycin for
14 days as a first choice for the treatment
and prophylaxis of pertussis. Antibiotics
should be started no later than 3 weeks
after the onset of cough. Trimethoprim-
sulfamethoxazole can be used as an alter-
native treatment for patients who do not
tolerate erythromycin. Prophylaxis is rec-
ommended for all household and close
contacts if pertussis is highly suspected.5
The American Academy of Pediatrics
recommends the use of azithromycin and
clarithromycin as an alternative treatment
for patients who do not tolerate erythro-
mycin.5
A national consensus conference on
pertussis held in Canada recommended
prophylaxis for household contacts of an
infant aged <1 year, pregnant women dur-
ing the third trimester, and for vulnerable
individuals who have had face-to-face
exposure, or have shared confined air for
>1 hour.6
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